0 268

Cited 52 times in

Treatment of Behcet's Disease

DC Field Value Language
dc.contributor.author방동식-
dc.date.accessioned2020-07-03T17:19:15Z-
dc.date.available2020-07-03T17:19:15Z-
dc.date.issued1997-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/177439-
dc.description.abstractBehçet's disease is characterized with multifactorial etiopathogenesis and multiclinical pictures. The treatment of patients with Behçet's disease is based on the severity of illness, and the most appropriate management of Behçet's disease requires a multidisciplinary approach. Although various therapeutic modalities have been employed for Behçet's disease, treatment is far from satisfactory. Treatment of Behçet's disease includes local, systemic, or surgical therapies. Limited success has been found with colchicine, azathioprine, indomethacin, cyclophosphamide, chlorambucil, levamisole, transfer factor, fibrinolytic therapy, and systemic corticosteroid. New therapeutic approaches have been introduced for Behçet's disease using cyclosporine, thalidomide, interferon, acyclovir, high-dose corticosteroids or cyclophosphamide pulse therapy, and FK 506. We suggest that therapeutic agents should be selected after thorough evaluation of the immune state of each patient by using various tests and by determining any aggravating or provoking factors involved. In general, a combination-agent regimen is more effective than a single-agent regimen. Early diagnosis and proper treatment can inhibit or at lease slow the progress of the disease remarkably.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdrenal Cortex Hormones/therapeutic use-
dc.subject.MESHBehcet Syndrome/therapy*-
dc.subject.MESHCyclophosphamide/therapeutic use-
dc.subject.MESHHumans-
dc.subject.MESHImmunosuppressive Agents/therapeutic use-
dc.subject.MESHTetracycline/therapeutic use-
dc.subject.MESHThalidomide/therapeutic use-
dc.subject.MESHZinc Sulfate/therapeutic use-
dc.titleTreatment of Behcet's Disease-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Dermatology (피부과학교실)-
dc.contributor.googleauthorDongsik Bang-
dc.identifier.doi10.3349/ymj.1997.38.6.401-
dc.contributor.localIdA01784-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid9509910-
dc.contributor.alternativeNameBang, Dong Sik-
dc.contributor.affiliatedAuthor방동식-
dc.citation.volume38-
dc.citation.number6-
dc.citation.startPage401-
dc.citation.endPage410-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.38(6) : 401-410, 1997-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.